Stock DNA
Pharmaceuticals & Biotechnology
CNY 12,256 Million (Mid Cap)
48.00
NA
1.30%
0.04
3.76%
1.88
Revenue and Profits:
Net Sales:
2,247 Million
(Quarterly Results - Mar 2026)
Net Profit:
104 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-2.15%
0%
-2.15%
6 Months
-16.77%
0%
-16.77%
1 Year
22.1%
0%
22.1%
2 Years
52.13%
0%
52.13%
3 Years
-15.58%
0%
-15.58%
4 Years
-36.0%
0%
-36.0%
5 Years
-43.09%
0%
-43.09%
Dian Diagnostics Group Co. Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-3.56%
EBIT Growth (5y)
-26.20%
EBIT to Interest (avg)
5.38
Debt to EBITDA (avg)
0.94
Net Debt to Equity (avg)
0.23
Sales to Capital Employed (avg)
1.13
Tax Ratio
38.09%
Dividend Payout Ratio
485.44%
Pledged Shares
0
Institutional Holding
0.12%
ROCE (avg)
14.59%
ROE (avg)
19.22%
Valuation key factors
Factor
Value
P/E Ratio
48
Industry P/E
Price to Book Value
1.81
EV to EBIT
23.99
EV to EBITDA
13.06
EV to Capital Employed
1.78
EV to Sales
1.21
PEG Ratio
0.24
Dividend Yield
1.35%
ROCE (Latest)
7.43%
ROE (Latest)
3.76%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot : Dec 2016
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.12%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
2,247.00
2,530.40
-11.20%
Operating Profit (PBDIT) excl Other Income
192.60
168.20
14.51%
Interest
32.70
52.50
-37.71%
Exceptional Items
2.10
-8.00
126.25%
Consolidate Net Profit
104.20
-36.40
386.26%
Operating Profit Margin (Excl OI)
85.70%
13.90%
7.18%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is -11.20% vs -3.75% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 386.26% vs -136.47% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
10,064.60
12,166.60
-17.28%
Operating Profit (PBDIT) excl Other Income
1,026.70
1,226.90
-16.32%
Interest
176.10
221.70
-20.57%
Exceptional Items
-74.40
-424.20
82.46%
Consolidate Net Profit
145.60
-169.20
186.05%
Operating Profit Margin (Excl OI)
45.00%
41.20%
0.38%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -17.28% vs -9.03% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 186.05% vs -129.09% in Dec 2024
About Dian Diagnostics Group Co. Ltd. 
Dian Diagnostics Group Co. Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






